Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

Wyeth

Status: Completed

Conditions: Escherichia Coli Infections; Klebsiella Infections

Treatments: Drug: vancomycin-resistant enterococci and ESBL

Study type: Observational

Funder types: Industry

Identifiers

NCT00167986

101498

Details and patient eligibility

About

To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients admitted to or transferred to the MICU.
• Patients 18 years of age or older.
• Provide written informed consent.

Exclusion criteria

• Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae.
• Patients who have hypersensitivity to penicillin.
• Any underlying conditions or diseases that will be ultimately fatal within 48 hours.
• Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.